Kestra Medical Technologies, Ltd. (KMTS) Q1 FY2027 earnings
$KMTSearnings

Kestra Medical Technologies, Ltd. (KMTS) Q1 FY2027 earnings

September 14, 2026 · SharpeIQ Research Desk

Reported results

Guidance

Notes

The company increased FY27 revenue guidance from prior guidance of $137 million. GAAP net loss includes a loss on extinguishment of debt of $6.3 million in the current quarter.

Price and volatility reaction

The stock moved +4.7% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release24.062026-09-14
Close after release25.182026-09-15
Realised move+4.7%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-14 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV, mispricing and the full options analytics suite — free to start.

Launch the app →